Bio-Path Holdings, Inc.

1.65 USD
-0.31 (-15.82%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Bio-Path Holdings, Inc. stock is down -17.5% since 30 days ago. The next earnings date is Aug 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 29.41% of the previous 16 July’s closed higher than June. 100% of analysts rate it a buy.

About Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company develops products based on DNAbilize, a drug delivery and antisense technology.